Background. Aspirin has a beneficial role in prevention of cardiovascular and thromboembolic events. Patients may experience thromboembolic events despite aspirin treatment, a phenomenon called aspirin resistance. We evaluated the frequency of aspirin resistance and its correlation with clinical and biochemical parameters among patients with nephrotic syndrome (NS). Methods. A total of 83 patients (50 males, 33 females, age range 18-79 years) with NS using aspirin 100 mg/ day were included in the study. Demographic information and aetiology of NS based on the histology of a renal biopsy were recorded for each patient. Blood samples were drawn to investigate the association of aspirin resistance with inflammation and thrombotic risk factors. Aspirin resistance was defined as a normal collagen/ epinephrine closure time <159 s using a platelet function analyzer (PFA-100). Results. Aspirin resistance was determined in 51 patients (61.4%). The number of patients exposed to azathioprine therapy was significantly higher in the aspirin-sensitive group (P ¼ 0.043), whereas patients exposed to cyclosporine therapy were significantly higher in the aspirin-resistant group (P ¼ 0.017). More patients in the aspirin-resistant group were on angiotensin-converting enzyme inhibitor therapy compared with the aspirin-sensitive group (P ¼ 0.024). The aspirin-resistant group showed significantly higher serum low-density lipoprotein cholesterol (LDL-C) (151 6 47 versus 104 6 21 mg/dL; P < 0.001), triglyceride levels (192 6 116 versus 134 6 82 mg/dL; P ¼ 0.015) and glomerular filtration rates (91.8 6 43.0 versus 74.0 6 35.6 mL/min/1.73m 2 ; P ¼ 0.044) compared with the aspirinsensitive group. In multivariate analysis, LDL-C was the only parameter associated independently with aspirin resistance [odds ratio (OR) 1.04, 95% confidence interval (CI) 1.02-1.06; P ¼ 0.004]. Conclusions. A significant number of patients with NS are resistant to aspirin therapy. Serum LDL-C level is closely associated with aspirin resistance in NS.
Introduction
The nephrotic syndrome (NS) is defined by a urinary protein level exceeding 3.5 g/1.73 m 2 /day occurring in association with edema, hypoalbuminemia and hyperlipidemia. Patients with NS have an increased risk of venous and arterial thromboembolic complications [1] . Thromboembolism represents the highest life-threatening risk to these patients. The incidence of thromboembolic complications has been estimated at~35% of patients with NS [2] . The disease is also associated with an increased risk of atherosclerosis and coronary heart disease, probably because of hypercholesterolemia and hypertriglyceridemia commonly seen in these patients [3] . The absolute risk of cardiovascular and thromboembolic events including deep vein thrombosis, myocardial infarction, ischemic stroke and peripheral artery disease has been demonstrated to be several times higher in patients with NS than the annual incidences in the general population [4] . Considerable data suggest that a hypercoagulable state exists in the setting of NS. However, the exact underlying mechanism of venous and arterial thromboembolism observed in these patients is not fully established. Studies examining platelet abnormalities have suggested a role for platelet activation and aggregation in the development of thromboembolism in NS [1, [5] [6] [7] . Antiplatelet agents are frequently used for the prevention of nephrosis-induced thromboembolism, although it is uncertain whether they have a significant effect. Among these agents, low-dose aspirin is commonly preferred in clinical practice. Aspirin has a beneficial role in prevention of cardiovascular and thromboembolic events in patients at high risk for atherothrombotic diseases [8] . However, patients may experience thromboembolic events despite aspirin treatment, a phenomenon called aspirin resistance. This term has also been used to describe persistent platelet activation, demonstrated by platelet function tests despite prescription of a regular therapeutic dose of aspirin [9] . To date, no clinical trial has investigated the existence of aspirin resistance in NS. In this study, we evaluated the frequency of aspirin resistance and its relation with clinical and biochemical parameters among patients with NS.
Materials and methods

Patient population
We prospectively enrolled 83 patients (50 males, 33 females, age range 18-79 years) between September 2008 and September 2009. The patients were recruited from consecutive patients presenting to our outpatient nephrology clinic for follow-up treatment of NS. All patients were on regular aspirin treatment with 100 mg daily. We recorded the demographic information of each patient including age, gender, body mass index (BMI), smoking status, aetiology of NS based on the histology of a renal biopsy, duration of the disease, immunosuppressive and non-immunosuppressive drugs used for the treatment and the length of use of each immunosuppressive drug. Patients with remission and duration of remission were also recorded. In order to analyze the relationship between aspirin resistance and low-density lipoprotein cholesterol (LDL-C), the patients were divided into quartiles according to serum LDL-C levels: low (LDL-C 98 mg/dL), low-medium (LDL-C 99-125 mg/dL), medium-high (LDL-C 126-158 mg/dL) and high (LDL-C ! 159 mg/dL). Exclusion criteria included are as follows: ingestion of clopidogrel, ticlopidine, dipyridamole or other non-steroidal anti-inflammatory drugs; administration of heparin or low-molecular weight heparin within 24 h before enrollment; family or personal history of bleeding disorders; history of myeloproliferative diseases; malign paraproteinemias; diabetic nephropathy; hemoglobin level l<8 g/dL; platelet count <150 000/mm 3 or >450 000/mm 3 or history of drug-induced thrombocytopenia. The study protocol was approved by the local ethics committee. Informed consent was taken from all participants.
Laboratory measurements
Blood samples were obtained by trained personnel from all participants via antecubital venipuncture in the fasting state. Serum levels of hs-CRP were measured by nephelometry (N high-sensitivity C-reactive protein; Dade Behring, Mannheim, Germany). The assay sensitivity was 0.017 mg/dL and normal range <0.5 mg/dL. Plasma homocysteine levels were measured by Immulite 1000 immunoassay system (Siemens Homocysteine Kit; Siemens Healthcare Diagnostics, Barcelona, Spain) with normal values ranging from 5 to 12 lmol/L. Fibrinogen levels in plasma were assayed by the clotting method of Clauss, using Sysmex CA-7000 System Assay (Dade Thrombin Reagent; Dade Behring). Normal values ranged from 180 to 350 mg/dL. Other biochemical variables were analyzed using standard laboratory techniques for hospital use. Glomerular filtration rate (GFR) was estimated by the four-variable Modification of Diet in Renal Disease Study equation for each participant. A 24-h urine sample was collected for the measurement of albumin and protein excretion rate in all subjects.
Platelet function analysis
Blood samples were obtained from the patients by a clean puncture of an antecubital vein with minimal hemostasis. The samples were collected in anticoagulant tubes with 3.8% sodium citrate after the initial 2 mL were discarded to avoid spontaneous platelet activation. The last dose of aspirin was administered 1-24 h before blood sampling. The effect of aspirin was assessed using the platelet function analyzer (PFA-100) system (Dade Behring). PFA-100 tests were performed within 1 h after blood sampling. In our laboratory, the normal range of collagen/ epinephrine cartridge (CEPI) closure time (CT) value is between 82 and 159 s. Aspirin resistance determined by the PFA-100 was defined as a normal CEPI-CT (<159 s) despite aspirin treatment.
Statistics
Distribution of the variables was checked using the Kolmogorov-Smirnov test. Continuous variables with normal distribution were presented as mean AE SD. Variables with unequal distribution were expressed as medians (interquartile ranges: Q1-Q3). Categorical variables were presented as percentages and numbers. Student's t-test (if normally distributed) or Mann-Whitney U-test (if not normally distributed) were used to compare the continuous variables between the two groups. Categorical variables were compared with chi-square test. Pearson correlation analysis was used to evaluate the relationship between variables. Binary logistic regression analysis was used for multivariate analysis. The odd ratios (OR) and 95% confidence intervals (CI) were calculated. Statistical significance was considered at a two-tailed value of P <0.05. Statistical analyses were performed using SPSS software (Statistical Package for the Social Sciences, version 13.0; SPSS Inc., Chicago, IL).
Results
In the whole study group, membranous nephropathy was diagnosed in 27 cases, amyloidosis in 16, focal segmental glomerulosclerosis in 12, systemic lupus erythematosus in 7, crescentic glomerulonephritis in 5, IgA nephropathy in 5, membranoproliferative glomerulonephritis in 4, mesangial proliferative glomerulonephritis in 4 and minimalchange disease in 3.
Overall, aspirin resistance was demonstrated in 51 (61.4%) patients. There were no significant differences between the aspirin-resistant and aspirin-sensitive groups with regard to age, gender, BMI, tobacco use, aetiology of NS and duration of the disease. The number of patients who remained in complete remission and the remission duration of these patients did not differ between the aspirin-resistant and aspirin-sensitive groups (Table 1) . Immunosuppressive drugs administered for the treatment of patients during the disease period, the length of use of each immunosuppressive drug and non-immunosuppressive drugs which patients are currently on for the treatment of NS are presented in Table 2 . The number of patients who were exposed to azathioprine therapy was significantly higher in the aspirin-sensitive group, whereas the number of patients exposed to cyclosporine therapy was significantly higher in the aspirin-resistant group. In the aspirin-resistant group, the number of patients on angiotensin-converting enzyme (ACE) inhibitor therapy was significantly higher than in the aspirin-sensitive group.
Regarding the laboratory variables, serum LDL-C and triglyceride (TG) levels were significantly higher among patients in the aspirin-resistant group compared with the aspirin-sensitive group. Patients in the aspirin-resistant group also showed significantly higher GFRs than those in the aspirin-sensitive group. The aspirin-resistant group tended to have lower, although not statistically significant, serum albumin levels compared with the aspirinsensitive group (P ¼ 0.056). Complete blood counts, plasma fibrinogen and homocysteine levels, hs-CRP, 24-h urinary protein and albumin levels did not differ between the two groups ( Table 3) . Since univariate analysis revealed between-group differences with regard to serum LDL-C and TG levels, GFR, cyclosporine, azathioprine and ACE inhibitor use, we performed a multivariate logistic regression analysis including predictive parameters (serum LDL-C and TG levels, GFR, cyclosporine, azathioprine and ACE inhibitor use) along with non-predictive parameters (gender, statin use, albumin, fibrinogen, homocysteine, proteinuria). LDL-C was the only parameter associated independently with aspirin resistance (OR 1.04, 95% CI 1.02-1.06; P ¼ 0.004) ( Table 4) . In Pearson correlation analysis, the CT for CEPI was negatively correlated with LDL-C levels (r ¼ À0.432, P < 0.0001; Figure 1 ). The percentage of aspirin resistance increased in a graded fashion from the low-to high-LDL-C group. The percentage of aspirinresistant patients was 38.1% in each of low and lowmedium groups and 71.4% in the medium-high group. Interestingly, all patients in the high group, who had serum LDL-C levels >159 mg/dL, were resistant to aspirin therapy (P < 0.0001; Figure 2 ).
Discussion
The major finding of the present study was that a substantial number of patients with NS (61.4%) was resistant to low-dose aspirin therapy. This finding suggests that only a minority of patients with NS may benefit from aspirin as a preventative therapy against thromboembolic complications. Many studies have investigated the frequency of aspirin resistance in patients with cardiovascular diseases. Since different laboratory methods were used, a wide range of prevalence estimates of aspirin resistance (5.5-56%) has been reported [10] [11] [12] [13] [14] . The frequency of aspirin resistance has also been investigated in patients who are at increased risk for cardiovascular disease. In these studies, aspirin resistance has been reported to be 21.5% in diabetic patients and 21% in hypertensive patients [15, 16] . Since this is the first study to date that evaluates the frequency of aspirin resistance in nephrotic patients, we do not have the possibility to compare our findings with the other studies. Nonetheless, considering the prevalence of aspirin resistance in various diseases, we found a relatively high frequency of aspirin resistance in nephrotic patients.
Patients with various forms of primary and secondary NS have the risk of developing thromboembolic complications [1, 2] . Low levels of serum albumin and heavy proteinuria, particularly observed in membranous nephropathy, membranoproliferative glomerulonephritis, minimal-change disease and renal amyloidosis, amplify the risk of thrombosis [17] . Although multiple underlying mechanisms of thrombophilic state of the NS have been described, it is not well understood why certain conditions have such a close relation with thromboembolic complications. Increased platelet aggregation has been proposed to be one of the underlying mechanisms leading to the prothrombotic state in NS. A low serum albumin is inversely correlated with fibrinogen and correlated with anti-thrombin III and increased platelet aggregability [18, 19] . Hypoalbuminemia results in increased availability of normally albumin-bound arachidonic acid, leading to increased formation of thromboxane A 2 in platelets, a stimulus for platelet aggregation [20] . Hyperfibrinogenemia may also contribute to the Aspirin resistance in NSplatelet hyperaggregability in NS [2] . In vitro studies revealed increased platelet aggregation with increasing concentrations of fibrinogen in stirred platelet-rich suspensions and a correlation between plasma fibrinogen and ADP-stimulated platelet aggregability in nephrotic patients [5, 7] . Since the increased platelet aggregation is one of the suggested mechanisms of aspirin resistance, it is not surprising that nephrotic patients have been found to be highly resistant to aspirin therapy. In the present study, levels of serum albumin tended to be lower and rate of proteinuria tended to be higher in the aspirinresistant group. However, none of these parameters predicted the aspirin resistance. The aetiology of NS and serum fibrinogen levels were also not predictive of aspirin resistance. In this study, we did not demonstrate an association between aspirin resistance and age, gender or smoking status. Gum et al. showed a significant difference between the aspirin-sensitive and aspirin-resistant groups with regard to age, gender and cigarette smoking in patients with cardiovascular disease by using optical platelet aggregometry. However, these demographics were not different between the groups when they used the PFA-100 system [10] . In another study investigating the prevalence of aspirin resistance in diabetic patients using the PFA-100 system, age was associated independently with aspirin resistance but not gender or smoking status [15] .
Since all the patients in the study population had been diagnosed as having NS, they were given various treatment regimens including disease-specific immunosuppressive and non-immunosuppressive drugs until they were enrolled in the study. Some of the patients remained responsive to these medications, which induced complete remission. Thus, we also evaluated whether the disease duration, treatment regimens, remission rate and extension had any potential effects on aspirin resistance. However, except for the medications including azathioprine, cyclosporine and ACE inhibitors, these factors were not different between the aspirin-resistant and aspirin-sensitive groups. Though the number of patients exposed to azathioprine, cyclosporine and ACE inhibitors were significantly different between the aspirin-resistant and sensitive groups, none of them predicted the aspirin resistance in multivariate analysis. Inflammatory diseases may increase the expression of aspirin-insensitive inducible cyclooxygenase-2 enzyme, which is mainly expressed in monocytes, macrophages and endothelial cells leading to increased thromboxane A 2 synthesis. Progressive production of thromboxane A 2 may cause aspirin-resistant platelet activation [21] . However, the results of the studies investigating the effect of inflammation on aspirin resistance using the PFA-100 system are controversial. Homoncik et al. [22] proposed that systemic inflammation had a major impact on the results obtained by PFA-100 and may confound interpretation of platelet function. Modica et al. [23] reported that C-reactive protein (CRP) levels were independently associated with aspirin resistance measured by PFA-100 in patients with an acute coronary syndrome complicated by an infection. On the contrary, Ziegler et al. [24] found no difference in mean PFA-100 results between patients with peripheral arterial occlusive disease with elevated CRP levels and those without. Serum hs-CRP levels were not different between the aspirin-resistant and aspirinsensitive patients in the present study suggesting that aspirin responsiveness was not influenced by systemic inflammation in NS.
Hyperhomocysteinemia is an independent risk factor for atherosclerosis, thrombosis and other cardiovascular diseases [25, 26] . This may be secondary to the effects of elevated concentrations of circulating homocysteine on the vascular wall, platelet function and coagulation factors promoting the development of a pro-coagulant state [27] . Hyperhomocysteinemia may cause increased platelet aggregation due to the concentration-dependent inhibition of l-arginine transport and increased intracellular Ca 21 concentration [28] . However, these effects of hyperhomocysteinemia have not been investigated in nephrotic patients. In the present study, we also evaluated the association between aspirin resistance and homocysteine levels in NS. Plasma homocysteine levels were similar between the aspirin-resistant and aspirin-sensitive groups, and homocysteine was not a predictor for aspirin resistance in multivariate logistic regression analysis.
We demonstrated significantly higher serum LDL-C levels in patients with aspirin resistance. This finding was confirmed by the results of multivariate analysis showing that LDL-C was the only independent predictor for aspirin resistance in nephrotic patients. The OR for LDL-C was 1.04 in our model including several potential predictive factors for aspirin resistance. It was statistically significant with a 95% CI. Based on this model, it can be concluded that each increment in LDL-C levels is associated with an increase in the odds of aspirin resistance by~4% controlling for other variables in the model.
Several studies have suggested an association of aspirin resistance with hypercholesterolemia. Yildirir et al. found an association between aspirin resistance and hyperlipidemia in renal transplant recipients [29] . In coronary artery disease patients, increased acetylsalicylic acid insensitivity of platelet aggregation positively correlated with increased serum TG and total cholesterol [30] . The association between hypercholesterolemia and aspirin resistance may depend on the effects of hypercholesterolemia on platelet aggregability. Indeed, several studies have demonstrated increased platelet aggregability in hypercholesterolemic patients [31, 32] . High levels of cholesterol-rich LDL may alter platelet function via binding to the LDL receptors on platelets leading to the exchange of lipids between the LDL particles and the plasma membrane. This process makes platelets in vitro more responsive to stimulating agents leading to increased aggregability [33] . Hypercholesterolemia is one of the factors contributing to the platelet hyperaggregability seen in nephrotic patients [2, 7] . It has been suggested that elevated levels of LDL-C may increase platelet aggregation in nephrotic patients due to the observation that HMG-CoA reductase inhibitor therapy improves platelet hyperaggregability in nephrotic patients [34] . The high frequency of aspirin resistance in our study may be explained by the increased platelet aggregability secondary to the elevated serum LDL-C levels. Although we did not directly measure the platelet aggregability, we demonstrated a negative correlation between serum LDL-C levels and CT for EPI. Furthermore, percentage of patients with aspirin resistance significantly increased with the increasing levels of serum LDL-C in quartile groups. However, since serum LDL-C levels and aspirin resistance were measured at the same point in time, a cause and effect relationship is not certain. To demonstrate such a relationship between serum LDL-C levels and aspirin resistance, a longitudinal assessment of aspirin resistance may be considered after an optimal therapeutic attempt in order to reduce LDL-C below recommended target levels.
In conclusion, the present study demonstrated that a substantial number of patients with NS were resistant to low-dose aspirin therapy. Such an increased frequency of aspirin resistance was associated with hypercholesterolemia in nephrotic patients. Therefore, hypercholesterolemia, particularly the increased levels of serum LDL-C, may constitute a significant independent predictor of the development of resistance to aspirin in this particular group of patients.
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